Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3082% above fair value
$1.72−0.06 (-3.37%)
Close on Nov 18, 2026Market cap $765.32MP/E –Yield –
Lexicon Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Lexicon Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $41.47M, down 29.0% year over year. For fiscal 2025 it was $49.80M, up 60.2% from the year before. Over ten years it grew -9.1% a year on average. The highest annual figure on record is $322.07M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.80M | +60.2% |
| FY2024 | Dec 31, 2024 | $31.08M | +2481.5% |
| FY2023 | Dec 31, 2023 | $1.20M | +766.2% |
| FY2022 | Dec 31, 2022 | $139.00K | -53.4% |
| FY2021 | Dec 31, 2021 | $298.00K | -98.8% |
| FY2020 | Dec 31, 2020 | $24.00M | -92.5% |
| FY2019 | Dec 31, 2019 | $322.07M | +409.5% |
| FY2018 | Dec 31, 2018 | $63.21M | -31.1% |
| FY2017 | Dec 31, 2017 | $91.69M | +15.7% |
| FY2016 | Dec 31, 2016 | $79.26M | -39.0% |
| FY2015 | Dec 31, 2015 | $130.01M | +468.9% |
| FY2014 | Dec 31, 2014 | $22.85M | +928.5% |
| FY2013 | Dec 31, 2013 | $2.22M | +104.0% |
| FY2012 | Dec 31, 2012 | $1.09M | -41.1% |
| FY2011 | Dec 31, 2011 | $1.85M | -62.3% |
| FY2010 | Dec 31, 2010 | $4.91M | -54.1% |
| FY2009 | Dec 31, 2009 | $10.70M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $692.00K | -97.6% |
| Q1 FY2026 | Mar 31, 2026 | $21.10M | +1572.1% |
| Q4 FY2025 | Dec 31, 2025 | $5.49M | -79.3% |
| Q3 FY2025 | Sep 30, 2025 | $14.18M | +710.4% |
| Q2 FY2025 | Jun 30, 2025 | $28.87M | +1652.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.26M | +11.7% |
| Q4 FY2024 | Dec 31, 2024 | $26.55M | +3682.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.75M | +980.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.65M | +419.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.13M | +4608.3% |
| Q4 FY2023 | Dec 31, 2023 | $702.00K | +2407.1% |
| Q3 FY2023 | Sep 30, 2023 | $162.00K | +315.4% |
| Q2 FY2023 | Jun 30, 2023 | $317.00K | +805.7% |
| Q1 FY2023 | Mar 31, 2023 | $24.00K | +71.4% |
| Q4 FY2022 | Dec 31, 2022 | $28.00K | +21.7% |
| Q3 FY2022 | Sep 30, 2022 | $39.00K | -83.3% |
| Q2 FY2022 | Jun 30, 2022 | $35.00K | +29.6% |
| Q4 FY2021 | Dec 31, 2021 | $14.00K | -93.0% |
| Q3 FY2021 | Sep 30, 2021 | $23.00K | -99.7% |
| Q2 FY2021 | Jun 30, 2021 | $234.00K | -97.4% |
| Q1 FY2021 | Mar 31, 2021 | $27.00K | -99.7% |
| Q4 FY2020 | Dec 31, 2020 | $199.00K | -97.7% |
| Q3 FY2020 | Sep 30, 2020 | $6.63M | -97.7% |
| Q2 FY2020 | Jun 30, 2020 | $9.16M | -5.4% |
| Q1 FY2020 | Mar 31, 2020 | $8.00M | -13.2% |
| Q4 FY2019 | Dec 31, 2019 | $8.73M | -48.9% |
| Q3 FY2019 | Sep 30, 2019 | $294.45M | +4126.9% |
| Q2 FY2019 | Jun 30, 2019 | $9.68M | -29.8% |
| Q1 FY2019 | Mar 31, 2019 | $9.22M | -63.7% |
| Q4 FY2018 | Dec 31, 2018 | $17.07M | -49.7% |
| Q3 FY2018 | Sep 30, 2018 | $6.97M | -74.8% |
| Q2 FY2018 | Jun 30, 2018 | $13.80M | +14.2% |
| Q1 FY2018 | Mar 31, 2018 | $25.37M | +41.3% |
| Q4 FY2017 | Dec 31, 2017 | $33.97M | +47.4% |
| Q3 FY2017 | Sep 30, 2017 | $27.67M | -0.2% |
| Q2 FY2017 | Jun 30, 2017 | $12.09M | – |
| Q1 FY2017 | Mar 31, 2017 | $17.96M | – |
| Q4 FY2016 | Dec 31, 2016 | $23.04M | – |
| Q3 FY2016 | Sep 30, 2016 | $27.72M | – |
See a number that looks wrong?